New Phase 3 Data: Sanofi’s Anti-OX40 Ligand Monoclonal Antibody Shows Efficacy, Safety for AD in Patients 12 Years and Up

Amlitelimab, Sanofi’s fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is continuing to show promise in atopic dermatitis (AD), finds two additional global Phase 3 studies: SHORE and COAST 2.